Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News

Ms. Skinner has financial acumen, accounting and auditing expertise, with understanding of risk management compliance frameworks and control oversight. Her listed company experience and expertise in capital management and corporate development enable her to challenge management constructively. Ms. Skinner has experience in auditing, accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. She has served as a Director of Create Foundation Limited (since June 2004). She previously also served as a Director of HSBC Bank Australia Limited (from April 2017 to April 2023) and as an independent Non-Executive Director of QBE Insurance Group Limited (from October 2014 to May 2024). She is chair of Risk Commitee and member of People, Culture Committee and Disclosure Commitee.

Ms McDonald is a Director of several ASX-listed life science companies including CSL and Nanosonics. She brings experience in financial markets, mergers and acquisitions, regulatory policy, remuneration, risk management and compliance. Ms McDonald practised for 30 years as a commercial lawyer for law firm Ashurst Australia and was previously a long-serving member of the Australia Takeovers Panel.

Dr. Behrenbruch has more than two decades of radiopharmaceuticals experience and a track record in global healthcare and biotechnology entrepreneurship and technology commercialization. He brings a blend of technical expertise and executive leadership to guide Telix as it enters the next stage of its strategy. Dr. Behrenbruch has a focus on purpose and values-leadership, and is versed in all aspects of running a publicly listed company as both CEO and Director in the U.S. and Australia. Previously, Dr. Behrenbruch served as Chief Executive Officer at Mirada Solutions (now Mirada Medical Limited) (from July 2001 to December 2002), President at CTI Molecular Imaging (now Siemens Healthcare) (from August 2003 to September 2006), Chief Executive Officer at Fibron Technologies, Inc. (from June 2008 to December 2011) and Chief Executive Officer at ImaginAb, Inc. (from October 2007 to February 2015). He served as a Director at Siemens Molecular Imaging Ltd (from May 2005 to September 2006), Momentum Biosciences LLC (from July 2007 to June 2009), Radius Health Ltd (now Adaptix Ltd) (from May 2009 to February 2011). Dr. Behrenbruch was the Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre) (from October 2012 to July 2014). He is member of Disclosure Commitee.

Dr. Nelson's experience in the investment community, including in life sciences, brings a sound investment perspective to the implementation of Telix's strategy. Dr. Nelson has served as Chairman of the Caledonia Investments Group (since January 2012) and as a Director of The Caledonia Foundation (since August 2002). He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group (from February 1992 to January 2012). Dr. Nelson has served as Chairman of Art Exhibitions Australia (since 2019), Director of the Mindgardens Neuroscience Network (since February 2018), Governor of the Florey Neurosciences Institute (since October 2007), and Director of Kaldor Public Art Projects (since October 2005). He is member of risk committee and People and Culture Committee.

-

-

-

-

-

-

-

-

-

-